Abbvie Inc  $158.02

AbbVie, Inc. is a biopharmaceutical company that specializes in researching, developing and selling pharmaceutical products. With its headquarters located in North Chicago, Illinois, AbbVie currently employs 50,000 full-time employees. The company went public on 2013-01-02 and has since been offering a range of products in various therapeutic categories. AbbVie's products include immunology products like Humira, Skyrizi, and Rinvoq, oncology products such as Imbruvica and Venclexta, and aesthetics products like Botox Cosmetic, Juvederm Collection, and others. The company also offers neuroscience products such as Botox Therapeutic, Vraylar, Duopa, and Duodopa, Ubrelvy; eye care products like Lumigan, Alphagan, and Restasis; women's health products such as Lo Loestrin, Orilissa, and others. Additionally, AbbVie provides other products like Mavyret, Creon, Lupron, Linzess, and Synthroid. AbbVie's shares are sold to wholesalers, government agencies, healthcare facilities, and independent retailers. As of today, the stock price today for AbbVie, Inc. is available for premarket viewing. With a large market cap, AbbVie, Inc. continues to discover and develop innovative antibody medicines that target difficult-to-drug disease-causing proteins such as G protein-coupled receptors (GPCRs).